Idraparinux sodium for prevention of stroke in patients with atrial fibrillation - horizon scanning review
NHSC
Record ID 32004000888
English
Authors' objectives:
This study aims to summarise the currently available evidence on idraparinux sodium for prevention of stroke in patients with atrial fibrillation.
Authors' recommendations:
Idraparinux sodium (SanOrg-34006) is a long-acting antithrombotic agent in phase III clinical trials for the prevention of stroke in patients with atrial fibrillation (AF). It is a methylated derivative of the synthetic pentasaccharide fondaparinux, and is administered as a once weekly subcutaneous injection. It is not clear at this stage if idraparinux is intended for all patients with AF, or for patients with AF and one or more other risk factors for stroke. Idraparinux is also in phase III clinical trials for the treatment and long-term secondary prevention of venous thromboembolism (VTE).
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2004
URL for published report:
http://www.psy-flow.com/sites/psy-flow/files/docs/flow.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Anticoagulants
- Atrial Fibrillation
- Stroke
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.